Description of Medical ServiceReduction of intraocular pressure is the only known modifiable glaucoma risk factor. Micro-bypass glaucoma surgery can be used to reduce intraocular pressure in open angle glaucoma (in patients with no current cataract co-morbidity or patients who have already undergone cataract surgery) following failure or intolerance to more conservative therapies (medication to reduce intraocular pressure and laser trabeculoplasty) when the patient is a candidate for incisional surgery. MINIject micro-bypass stent system can be inserted into the suprachoroidal space during micro-bypass surgery to enhance drainage of aqueous outflow into the suprachoroidal space to reduce intraocular pressure, reducing reliance on topical hypotensive medication.
Description of Medical ConditionGlaucoma is group of complex eye diseases leading to chronic and progressive damage to the optic nerve and progressive, irreversible vision loss. It is a major public health problem, as glaucoma is the leading cause for irreversible visual impairment and the second leading cause for blindness worldwide. Reduction of intraocular pressure is the only known modifiable glaucoma risk factor that can reduce progressive loss of vision and is associated with improved health outcomes including reduced visual loss and improvements in quality of life.
Reason for ApplicationNew MBS item
Medical Service TypeTherapeutic technology
Previous Application Number/sNot applicable
Application Summary and PICO SetApplication Summary (PDF 263 KB)
Application Summary (Word 45 KB)
PICO Set (PDF 666 KB)
PICO Set (Word 218 KB)
Consultation SurveyConsultation Survey (PDF 165 KB)
Consultation Survey (Word 28 KB)
MSAC consultation input must be received by no later than Friday, 16 February 2024 for it to be considered by MSAC at its April 2024 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process